Plants use in the management of viral respiratory infections, as in COVID-19

INTERVENTION: 56229 D20.215.784.844 The total of 240 participants, 120 in each group, placebo and agent.The number of shots (twice daily) and the duration of treatment (14 days) follow the regimen in clinical studies that evaluated the use of lopinavir/ritonavir in the treatment of COVID‐19. These drugs are known antivirals, with inhibitory properties of chemotrypsin‐like protease (3CL protease), a mechanism of action described for compounds isolated from Achyrocline satureioides, as described above. CONDITION: B34.2 Coronavirus Infections; Respiratory Tract Diseases PRIMARY OUTCOME: Reduction in the number of days of symptoms such as cough, dyspnea and headache, assessed by questionnaire and daily follow‐up. Data collected on the first day of tea drinking and throughout the 14 days daily. SECONDARY OUTCOME: 50% reduction in cough days, measured through daily questionnaires over the 14 days of intervention INCLUSION CRITERIA: Older than 18 years; suspected coronavirus infection